You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Claims for Patent: 8,409,799


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 8,409,799
Title:Diagnostic test for cardiomyopathy
Abstract: Methods and compositions relating to diagnosing and treating cardiomyopathy and particularly relating to methods and compositions for diagnosing and treating arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) are described. Provided are methods for screening for, diagnosing or detecting a risk of developing arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) comprising detecting the presence of a transmembrane protein 43 (TMEM43) disease associated variant in a sample of a subject, wherein the presence of a TMEM43 disease variant is indicative that the subject has ARVD/C or an increased risk of developing ARVD/C compared to an individual having wild type TMEM43.
Inventor(s): Young; Terry-Lynn (St. John\'s, CA), Hodgkinson; Kathy (St. John\'s, CA), Connors; Sean (St. John\'s, CA), Parfrey; Patrick (St. John\'s, CA), Haywood; Annika (St. John\'s, CA), Merner; Nancy (St. John\'s, CA), French; Vanessa (Torbay, CA)
Assignee: Genesis Group Inc. (St. John\'s, CA)
Application Number:12/339,877
Patent Claims:1. A method of screening for, diagnosing and/or detecting an increased risk of developing arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) in a human subject comprising: a) obtaining a sample from the subject; b) assaying the sample for the presence of the and detecting a T variant in a transmembrane protein 43 (TMEM43) nucleic acid molecule at nucleotide position corresponding to 171 of SEQ ID NO:1 thereby identifying the subject as having ARVD/C or an increased risk of developing ARVD/C, the assaying comprising hybridizing a probe and/or primer to the TMEM43 nucleic acid molecule.

2. The method of claim 1, wherein the TMEM43 nucleic acid molecule is a genomic nucleic acid molecule.

3. The method of claim 1, wherein the TMEM43 nucleic acid molecule is a cDNA or mRNA nucleic acid molecule.

4. The method of claim 1, wherein the sample comprises blood, a white blood cell, cardiac tissue, a cardiac cell and/or a nucleated cell.

5. The method of claim 1, wherein the subject is presymptomatic.

6. The method of claim 1, wherein the subject has at least one blood relation with ARVD/C.

7. The method of claim 1, wherein the TMEM43 variant is detected by one or more of genotyping, PCR, RT-PCR, NASBA, or microarray.

8. A method of treatment for subjects with ARVD/C and/or a risk of developing ARVD/C comprising: a) detecting the TMEM43 T variant according to claim 1; b) providing ICD therapy for a subject having the TMEM43 T variant.

9. A method of screening for, diagnosing and/or detecting an increased risk of developing arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) in a human subject comprising: a) obtaining a sample from the subject; b) assaying the sample for the presence of and detecting a T variant in a transmembrane protein 43 (TMEM43) nucleic acid molecule at nucleotide position corresponding to 171 of SEQ ID NO:1 thereby identifying the subject as having ARVD/C or an increased risk of developing ARVD/C, the assaying comprising: amplifying the TMEM43 nucleic acid molecule using one or more primers selected from SEQ ID NOS: 19, 20, 23, 24, 43 and 44 and/or hybridizing a probe comprising 16-20 nucleotides of SEQ ID NO:53 to the TMEM43 nucleic acid molecule to detect the T variant in the sample from the subject.

10. The method of claim 9, wherein the one or more primers comprise SEQ ID NO:43 and 44.

11. The method of claim 9, wherein the amplified TMEM43 nucleic acid molecule is sequenced to detect the presence of the T variant.

12. The method of claim 4, wherein the sample is a blood sample.

13. A method of screening for, diagnosing and/or detecting an increased risk of developing arrythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) in a human subject comprising: a) obtaining a sample from the subject; b) isolating mRNA from said sample, and deriving from it corresponding DNA (cDNA); c) assaying the cDNA for the presence of and detecting a T variant in a transmembrane protein 43 (TMEM 43) nucleic acid molecule at nucleotide position corresponding to nucleotide 171 of SEQ ID NO: 1 thereby identifying the subject as having ARVD/C or an increased risk of developing ARVD/C, the assaying comprising hybridizing a probe and/or primer to the TMEM43 nucleic acid molecule.

14. The method of claim 13 wherein the assay comprises amplifying the TMEM43 nucleic acid molecule using one or more primers selected from SEQ ID NOS: 19, 20, 23, 24 and/or hybridizing a probe to the amplified TMEM43 nucleic acid molecule, the probe comprising 16-20 nucleotides of SEQ ID NO: 53.

15. The method of claim 14, wherein the amplified TMEM43 nucleic acid molecule is sequenced to detect the presence of the T variant.

16. A method of screening for, diagnosing and/or detecting an increased risk of developing arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) in a human subject comprising a) obtaining a sample from the subject; b) isolating genomic DNA from said sample; c) assaying the genomic DNA and detecting a T variant in a genomic transmembrane protein 43 (TMEM 43) nucleic acid molecule at nucleotide position corresponding to nucleotide 171 of SEQ ID NO: 1, the assaying comprising sequencing the genomic TMEM43 nucleic acid molecule.

17. The method of claim 16, wherein the genomic TMEM43 nucleic acid molecule comprises an exon and/or exon/intron boundary.

18. The method of claim 16, wherein the isolated genomic DNA is amplified prior to sequencing.

19. The method of claim 18, wherein the isolated genomic DNA is amplified using one or more primers from the group consisting of SEQ ID NO: 43 and 44.

20. The method of claim 18 wherein the genomic DNA is isolated from a blood sample.

21. A method of screening for, diagnosing and/or detecting an increased risk of developing arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C) in a human subject comprising a) obtaining a sample from the subject; b) isolating mRNA from said sample; c) assaying the mRNA for the presence of and detecting a T variant in a transmembrane protein 43 (TMEM 43) nucleic acid molecule corresponding to nucleotide 171 of SEQ ID NO: 1 thereby identifying the subject as having ARVD/C or an increased risk of developing ARVD/C, the assaying comprising sequencing the TMEM43 nucleic acid molecule.

22. The method of claim 21 wherein the isolated mRNA is amplified prior to sequencing.

23. The method of claim 21 wherein mRNA is isolated from a blood sample.

Details for Patent 8,409,799

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 06/04/1986 ⤷  Try a Trial 2027-12-21
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b For Injection 103132 ⤷  Try a Trial 2027-12-21
Merck Sharp & Dohme Corp. INTRON A interferon alfa-2b Injection 103132 ⤷  Try a Trial 2027-12-21
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.